Literature DB >> 2026236

Effect of human antileucoprotease on experimental emphysema.

A Rudolphus1, J A Kramps, J H Dijkman.   

Abstract

Antileucoprotease (ALP), a potent inhibitor of human neutrophil elastase (HNE), may be a modulating factor in the pathogenesis of emphysema. Investigating the clearance of intratracheally-instilled ALP in hamsters, we observed a rapid clearance from the airway lumen within 60 min, whereafter the remaining 40% slowly decreased with a calculated half-life (T0.5) of 2.8 h. Lung tissue-associated ALP showed a peak at 40 min and slowly decreased (T0.5 approximately 3 h). In vivo efficacy of ALP on HNE-induced pulmonary lesions was studied by instillation of either 365 micrograms or 730 micrograms ALP, followed after 1 h by 420 micrograms HNE. Emphysema, haemorrhage and secretory cell metaplasia (SCM) were quantified 21 days after instillations. ALP was found to be able to inhibit emphysema and haemorrhage in a dose-related way, the decrease of haemorrhage being less pronounced. SCM was minimally affected. These results show that ALP inhibits efficiently the development of HNE-induced emphysema and, to a lesser extent, haemorrhage. We speculate that tissue-associated ALP might be responsible for this protection.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2026236

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  4 in total

1.  Oxidized mucus proteinase inhibitor: a fairly potent neutrophil elastase inhibitor.

Authors:  C Boudier; J G Bieth
Journal:  Biochem J       Date:  1994-10-01       Impact factor: 3.857

2.  Inhibition of human pancreatic proteinases by mucus proteinase inhibitor, eglin c and aprotinin.

Authors:  D Belorgey; S Dirrig; M Amouric; C Figarella; J G Bieth
Journal:  Biochem J       Date:  1996-01-15       Impact factor: 3.857

3.  Pharmacological activity of the C-terminal and N-terminal domains of secretory leukoprotease inhibitor in vitro.

Authors:  K Masuda; T Kamimura; K Watanabe; T Suga; M Kanesaki; A Takeuchi; A Imaizumi; Y Suzuki
Journal:  Br J Pharmacol       Date:  1995-07       Impact factor: 8.739

4.  Inhibition of NF-kappaB activation and augmentation of IkappaBbeta by secretory leukocyte protease inhibitor during lung inflammation.

Authors:  A B Lentsch; J A Jordan; B J Czermak; K M Diehl; E M Younkin; V Sarma; P A Ward
Journal:  Am J Pathol       Date:  1999-01       Impact factor: 4.307

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.